Pharmaceutical Executive-04-01-2015

Expert panel on rare disease highlights the challenges of serving expectant patients in this uniquely complex market access environment.

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.

Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres, whose career demonstrates that doing right starts with finding-and being-yourself.

The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.

Is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?

Making sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.

FDA is under pressure to moderate oversight of pharma advertising and promotion.

Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.

The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.

Does patient choice matter to antitrust enforcers?

Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.